Blue-violet light decreases VEGFa production in an in vitro model of AMD.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
02
2019
accepted:
01
10
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
21
3
2020
Statut:
epublish
Résumé
Blue light is an identified risk factor for age-related macular degeneration (AMD). The production of vascular endothelial growth factor (VEGF), leading to neovascularization, is a major complication of the wet form of this disease. We investigated how blue light affects VEGF expression and secretion using A2E-loaded retinal pigment epithelium (RPE) cells, a cell model of AMD. Incubation of RPE cells with A2E resulted in a significant increase in VEGF mRNA and, intracellular and secreted VEGF protein levels, but not mRNA levels of VEGFR1 or VEGFR2. Blue light exposure of A2E-loaded RPE cells resulted in a decrease in VEGF mRNA and protein levels, but an increase in VEGFR1 levels. The toxicity of 440 nm light on A2E-loaded RPE cells was enhanced by VEGF supplementation. Our results suggest that age-related A2E accumulation may result in VEGF synthesis and release. This synthesis of VEGF, which enhances blue light toxicity for the RPE cells, is itself suppressed by blue light. Anti-VEGF therapy may therefore improve RPE survival in AMD.
Identifiants
pubmed: 31644596
doi: 10.1371/journal.pone.0223839
pii: PONE-D-19-04856
pmc: PMC6808507
doi:
Substances chimiques
Eye Proteins
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0223839Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: CB and TV are Essilor employees. SP received fees for participating in a meeting organized by Essilor. SP received a grant from Essilor to work on light toxicity on retinal cells. No competing financial interests exist for PG, and DP. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors would like to declare the following patents/patent applications associated with this research: EP2602655 : filtre ophtalmique; EP2602654 : filtre ophtalmique; EP2602653 : Méthode de la détermination de la configuration d'un filtre ophtalmique; EP19305328 : filter for eye cone cells protection.
Références
J Biol Chem. 2008 May 2;283(18):11947-53
pubmed: 18326047
J Cell Mol Med. 2016 Aug;20(8):1457-66
pubmed: 26999719
Am J Physiol Cell Physiol. 2005 Apr;288(4):C913-20
pubmed: 15613498
Sci Signal. 2012 Sep 18;5(242):pe39
pubmed: 22990116
Exp Eye Res. 2005 May;80(5):595-606
pubmed: 15862166
Prog Retin Eye Res. 2016 Sep;54:64-102
pubmed: 27156982
J Recept Signal Transduct Res. 2003;23(2-3):239-54
pubmed: 14626450
Am J Clin Nutr. 1995 Dec;62(6 Suppl):1448S-1461S
pubmed: 7495246
Int J Retina Vitreous. 2016 Aug 15;2:19
pubmed: 27847637
Doc Ophthalmol. 2003 Jan;106(1):13-6
pubmed: 12675480
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17260-5
pubmed: 17088559
Apoptosis. 2009 Jan;14(1):31-41
pubmed: 19052872
Nutrients. 2013 May 29;5(6):1962-9
pubmed: 23760061
Ophthalmology. 2011 Jul;118(7):1380-5
pubmed: 21310490
Exp Eye Res. 2005 Apr;80(4):567-80
pubmed: 15781285
Cell Death Dis. 2018 Feb 19;9(3):287
pubmed: 29459695
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2115-21
pubmed: 10440268
J Photochem Photobiol B. 2001 Nov 15;64(2-3):144-61
pubmed: 11744401
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2303-8
pubmed: 10892877
Arch Ophthalmol. 2001 Feb;119(2):246-50
pubmed: 11176987
IUBMB Life. 2009 Sep;61(9):915-22
pubmed: 19658168
Br J Ophthalmol. 2013 Apr;97(4):389-94
pubmed: 23143904
Free Radic Biol Med. 2001 Jul 15;31(2):256-65
pubmed: 11440838
Cell Death Dis. 2013 Aug 29;4:e781
pubmed: 23990021
Exp Eye Res. 2006 Nov;83(5):1005-16
pubmed: 16713597
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1981-9
pubmed: 10845625
Arch Biochem Biophys. 2001 Jul 15;391(2):160-4
pubmed: 11437346
Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1052-60
pubmed: 15037568
Prog Retin Eye Res. 2008 Jul;27(4):331-71
pubmed: 18653375
PLoS One. 2008;3(11):e3554
pubmed: 18978936
Molecules. 2017 Apr 20;22(4):
pubmed: 28425969
Adv Exp Med Biol. 2003;533:205-11
pubmed: 15180266
Photochem Photobiol. 2009 Jul-Aug;85(4):966-9
pubmed: 19192204
Arch Ophthalmol. 2008 Oct;126(10):1396-403
pubmed: 18852418
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1190-7
pubmed: 19834034
Invest Ophthalmol Vis Sci. 2001 May;42(6):1356-62
pubmed: 11328751
Surv Ophthalmol. 2010 May-Jun;55(3):272-89
pubmed: 19883931
J Biol Chem. 2000 Dec 15;275(50):39625-30
pubmed: 11006290
J Cataract Refract Surg. 2006 Sep;32(9):1540-4
pubmed: 16931269
Prog Retin Eye Res. 2012 Jul;31(4):303-15
pubmed: 22465791
Arch Ophthalmol. 1992 Jan;110(1):99-104
pubmed: 1731731
J Cell Physiol. 2009 May;219(2):449-58
pubmed: 19180561
Acta Ophthalmol. 2013 Nov;91(7):e537-45
pubmed: 23742627
Free Radic Biol Med. 1997;22(7):1229-34
pubmed: 9098097
Br J Nutr. 2012 Jul 14;108(1):16-27
pubmed: 22018225
PLoS One. 2013 Aug 23;8(8):e71398
pubmed: 24058402
Cell Signal. 2008 Mar;20(3):569-79
pubmed: 18164591
Transl Vis Sci Technol. 2016 Mar 11;5(2):9
pubmed: 26981331
Sci Rep. 2020 Jul 24;10(1):12409
pubmed: 32710087
Br J Ophthalmol. 2008 Sep;92(9):1163-8
pubmed: 18669545
Retina. 2016 Apr;36(4):787-90
pubmed: 26441265
J Cell Physiol. 2009 Aug;220(2):469-75
pubmed: 19418485
J Natl Med Assoc. 1992 Apr;84(4):353-8
pubmed: 1507250
J Clin Invest. 2003 Jul;112(1):50-7
pubmed: 12840058
Arch Ophthalmol. 2006 Apr;124(4):529-35
pubmed: 16606879
Mol Aspects Med. 2012 Aug;33(4):295-317
pubmed: 22542780
J Cataract Refract Surg. 2009 Feb;35(2):354-62
pubmed: 19185255
Br J Ophthalmol. 2010 Nov;94(11):1533-9
pubmed: 20962354
Redox Biol. 2016 Apr;7:78-87
pubmed: 26654980
Microcirculation. 2002 Dec;9(6):513-22
pubmed: 12483548
Front Biosci. 2006 Jan 01;11:818-29
pubmed: 16146773
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6911-6918
pubmed: 28027565
Cell Death Dis. 2015 Nov 12;6:e1972
pubmed: 26561782